Strategic funding to accelerate adoption of ArgenTag’s Single-Cell Long-Read platform

We are thrilled to announce a strategic funding with participation from IndieBio (SOSV), Arben Ventures, Draper Cygnus and GRIDX to accelerate adoption of ArgenTag’s Single-Cell Long-Read platform.

This capital is fuel for our roadmap: Optimizing the Platform, Scaling Use Cases and Delivering the complete genomic truth that short-reads simply cannot see.

The industry is reaching a tipping point. To understand disease and development, researchers need the full picture—transcript isoform diversity and complex gene regulation at a single-cell level.

ArgenTag is proud to be leading this shift. As the only platform natively designed for long-read sequencing, we are unlocking a layer of biological insight that was previously unattainable.

“At Arben Ventures, we invest in scientists who redefine what’s possible in biology. ArgenTag is expanding a new category of single-cell long-read data, revealing biological information that short-read approaches simply cannot capture. This platform enables deeper insights into disease biology and creates a new foundation for both academic discovery and industry partnerships focused on novel therapeutic targets.” Ariel Ganz, Ph.D., co-founder at Arben Ventures.

The future of genomics is full-length. And we are just getting started.